AGC
ALXN

Angelo Gordon & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

Angelo Gordon & Co’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-105,000
Closed -$19.3M – 292
2021
Q2 		$19.3M Buy
105,000
+65,000
+163% +$11.2M 0.99% 10
2021
Q1 		$6.12M Buy
+40,000
New +$6.19M 0.53% 30

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Angelo Gordon & Co's ALXN Position: Q3 2021 in Review

Angelo Gordon & Co sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 105,000 shares — an estimated $19.3M sold.

Angelo Gordon & Co first reported a position in ALXN in Q1 2021 and held it in 2 quarters. The position peaked at $19.3M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Angelo Gordon & Co reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Angelo Gordon & Co sold 105,000 Alexion Pharmaceuticals shares in Q3 2021, an estimated $19.3M.
  • Angelo Gordon & Co first reported a position in Alexion Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Angelo Gordon & Co's Alexion Pharmaceuticals position peaked at $19.3M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Angelo Gordon & Co's 13F filing for Q3 2021, filed 15 Nov 2021.